OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
The Lancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 903-913
Open Access | Times Cited: 395
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
The Lancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 903-913
Open Access | Times Cited: 395
Showing 1-25 of 395 citing articles:
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
Norbert Stefan, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 4, pp. 284-296
Closed Access | Times Cited: 402
Norbert Stefan, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 4, pp. 284-296
Closed Access | Times Cited: 402
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 314
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 314
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2024), pp. gutjnl-330595
Open Access | Times Cited: 250
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2024), pp. gutjnl-330595
Open Access | Times Cited: 250
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Rohit Loomba, Manal F. Abdelmalek, Matthew J. Armstrong, et al.
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 6, pp. 511-522
Open Access | Times Cited: 247
Rohit Loomba, Manal F. Abdelmalek, Matthew J. Armstrong, et al.
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 6, pp. 511-522
Open Access | Times Cited: 247
Current status and future trends of the global burden of MASLD
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 697-707
Closed Access | Times Cited: 199
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 697-707
Closed Access | Times Cited: 199
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 153
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 153
The role of hepatokines in NAFLD
Norbert Stefan, Fritz Schick, Andreas L. Birkenfeld, et al.
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 236-252
Open Access | Times Cited: 144
Norbert Stefan, Fritz Schick, Andreas L. Birkenfeld, et al.
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 236-252
Open Access | Times Cited: 144
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world
Linda Henry, James M. Paik, Zobair M. Younossi
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 6, pp. 942-956
Closed Access | Times Cited: 140
Linda Henry, James M. Paik, Zobair M. Younossi
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 6, pp. 942-956
Closed Access | Times Cited: 140
MAFLD: a multisystem disease
Rosaria Maria Pipitone, Carlo Ciccioli, G. Infantino, et al.
Therapeutic Advances in Endocrinology and Metabolism (2023) Vol. 14
Open Access | Times Cited: 104
Rosaria Maria Pipitone, Carlo Ciccioli, G. Infantino, et al.
Therapeutic Advances in Endocrinology and Metabolism (2023) Vol. 14
Open Access | Times Cited: 104
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 100
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 100
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 91
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 91
Relationship between NAFLD and coronary artery disease: A Mendelian randomization study
Zhewen Ren, Pomme I. H. G. Simons, Anke Wesselius, et al.
Hepatology (2022) Vol. 77, Iss. 1, pp. 230-238
Open Access | Times Cited: 88
Zhewen Ren, Pomme I. H. G. Simons, Anke Wesselius, et al.
Hepatology (2022) Vol. 77, Iss. 1, pp. 230-238
Open Access | Times Cited: 88
Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance
Alan L. Hutchison, Federica Tavaglione, Stefano Romeo, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 6, pp. 1524-1541
Open Access | Times Cited: 86
Alan L. Hutchison, Federica Tavaglione, Stefano Romeo, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 6, pp. 1524-1541
Open Access | Times Cited: 86
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Hyeok‐Hee Lee, Han Ah Lee, Eun-Jin Kim, et al.
Gut (2023), pp. gutjnl-331003
Closed Access | Times Cited: 85
Hyeok‐Hee Lee, Han Ah Lee, Eun-Jin Kim, et al.
Gut (2023), pp. gutjnl-331003
Closed Access | Times Cited: 85
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease
Alessandro Mantovani, Christopher D. Byrne, Giovanni Benfari, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 2, pp. 180-191
Open Access | Times Cited: 83
Alessandro Mantovani, Christopher D. Byrne, Giovanni Benfari, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 2, pp. 180-191
Open Access | Times Cited: 83
Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
Joon Ho Moon, Seogsong Jeong, Heejoon Jang, et al.
EClinicalMedicine (2023) Vol. 65, pp. 102292-102292
Open Access | Times Cited: 79
Joon Ho Moon, Seogsong Jeong, Heejoon Jang, et al.
EClinicalMedicine (2023) Vol. 65, pp. 102292-102292
Open Access | Times Cited: 79
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 75
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 75
Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
Kyung‐Soo Kim, Sangmo Hong, Kyungdo Han, et al.
BMJ (2024), pp. e076388-e076388
Open Access | Times Cited: 59
Kyung‐Soo Kim, Sangmo Hong, Kyungdo Han, et al.
BMJ (2024), pp. e076388-e076388
Open Access | Times Cited: 59
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 59
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 59
Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies
Kai En Chan, Elden Yen Hng Ong, Charlotte Hui Chung, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 3, pp. 488-498.e14
Closed Access | Times Cited: 51
Kai En Chan, Elden Yen Hng Ong, Charlotte Hui Chung, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 3, pp. 488-498.e14
Closed Access | Times Cited: 51
NASH drug treatment development: challenges and lessons
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 48
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 48
Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies
Marta Maestri, Francesco Santopaolo, Maurizio Pompili, et al.
Frontiers in Nutrition (2023) Vol. 10
Open Access | Times Cited: 47
Marta Maestri, Francesco Santopaolo, Maurizio Pompili, et al.
Frontiers in Nutrition (2023) Vol. 10
Open Access | Times Cited: 47
Metabolic syndrome
Ian J. Neeland, Soo Lim, André Tchernof, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 45
Ian J. Neeland, Soo Lim, André Tchernof, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 45
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hannes Hagström, Ying Shang, Hannes Hegmar, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 944-956
Closed Access | Times Cited: 36
Hannes Hagström, Ying Shang, Hannes Hegmar, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 944-956
Closed Access | Times Cited: 36
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Michael H. Le, David Le, Thomas C. Baez, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 2, pp. 235-246
Open Access | Times Cited: 24
Michael H. Le, David Le, Thomas C. Baez, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 2, pp. 235-246
Open Access | Times Cited: 24
